Solid Biosciences Inc.
Financials
Valuation Metrics
Solid Biosciences Inc.'s Market Cap is $642M. At end of 2025 it was $534M. Ranked #2624 of 3,118 in US market (top 84%), #1118 of 1,474 on NASDAQ (top 76%), #201 of 265 in Pharmaceuticals, Biotechnology & Life Sciences (top 76%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $642M | US#2,624/3,118 Sec#201/265 |
| Revenue | $0.00 | US#2,858/3,118 Sec#193/265 |
| Net Income | $-207M | US—/3,118 Sec—/265 |
| Total Assets | $421M | US#2,819/3,118 Sec#178/265 |
| Net Assets | $374M | US#2,400/3,118 Sec#140/265 |
| Employees | 121 | US#2,578/3,118 Sec#163/265 |
| Value | ||
| P/B | 1.72x | US#1,121/3,118 Sec#51/265 |
| FCF Yield | -29.24% | US—/3,118 Sec—/265 |
| Profitability | ||
| ROE | -55.36% | US#2,693/3,118 Sec#166/265 |
| ROA | -49.24% | US#2,981/3,118 Sec#213/265 |
| Financial Health | ||
| Debt Ratio | 12.43% | US#138/3,118 Sec#57/265 |
| Total Debt | $20M | US#2,742/3,118 Sec#188/265 |
| FCF | $-188M | US#2,765/3,118 Sec#203/265 |
| Cash | $159M | US#1,910/3,118 Sec#128/265 |
| Current Ratio | 13.82x | US#179/3,118 Sec#54/265 |
| Performance | ||
| 1Y Return | 11.13% | US#1,250/3,118 Sec#112/265 |
| 1M Return | -12.55% | US#2,623/3,118 Sec#199/265 |
| From 52W High | -47.69% | US#2,516/3,118 Sec#187/265 |
| 1Y MDD | -50.94% | US#2,434/3,118 Sec#168/265 |
| Trading | ||
| Volume | 961,865 shares | US#1,764/3,118 Sec#173/265 |
| Trading Value | $6M | US#2,653/3,118 Sec#213/265 |
| Per Share | ||
| EPS | $-1.93 | US—/3,118 Sec—/265 |
| BPS | $3.49 | US#2,414/3,118 Sec#151/265 |
Company Info
Solid Biosciences Inc. is an American biotechnology firm dedicated to creating therapeutic solutions for Duchenne Muscular Dystrophy (DMD). Its most advanced experimental drug, SGT-001, is a gene transfer treatment currently in Phase I/II clinical trials, designed to encourage the production of functional dystrophin protein in patients' muscles. The company is also progressing with SGT-003, which represents a next-generation gene transfer therapy intended for DMD. Beyond specific drug candidates, Solid Biosciences is actively developing innovative platform technologies, such as "dual gene expression," a technique that allows for multiple therapeutic genes to be bundled into a single viral vector, and researching new capsid designs. The company maintains a strategic alliance through a collaboration and license agreement with Ultragenyx Pharmaceutical Inc., focusing on the joint development and market introduction of novel gene therapies for Duchenne Muscular Dystrophy. Founded in 2013, Solid Biosciences Inc. conducts its operations from its headquarters in Cambridge, Massachusetts.